VEGFA and neoplasm: In particular, bevacizumab (BVZ), a monoclonal antibody to vascular endothelial growth factor (VEGF), which was approved by the Food and Drug Administration (FDA) in 2009, has resulted in pharmacological debulking and volumetric tumor reduction leading to neurologic palliation and increased progression free survival (PFS) although there has been no significant improvement in OS (5–7).